S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The single greatest medical breakthrough of all time? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Forecast, Price & News

$1.50
-0.08 (-5.06%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.48
$1.61
50-Day Range
$1.50
$2.24
52-Week Range
$0.72
$2.69
Volume
278,257 shs
Average Volume
410,754 shs
Market Capitalization
$100.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Aquestive Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
300.0% Upside
$6.00 Price Target
Short Interest
Healthy
2.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Aquestive Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

693rd out of 962 stocks

Pharmaceutical Preparations Industry

312th out of 449 stocks


AQST stock logo

About Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Price History

AQST Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Wedbush Keeps Their Buy Rating on Aquestive Therapeutics (AQST)
Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities
H.C. Wainwright Remains a Buy on Aquestive Therapeutics (AQST)
See More Headlines
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Company Calendar

Last Earnings
8/07/2023
Today
9/25/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+300.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-54,410,000.00
Pretax Margin
-48.00%

Debt

Sales & Book Value

Annual Sales
$47.68 million
Book Value
($2.19) per share

Miscellaneous

Free Float
61,129,000
Market Cap
$100.10 million
Optionable
Not Optionable
Beta
2.63
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Daniel Barber (Age 47)
    CEO, Pres & Director
    Comp: $925.35k
  • Mr. Alexander Mark Schobel (Age 64)
    Chief Innovation & Technology Officer
    Comp: $672.69k
  • Ms. Lori J. Braender BSBA (Age 67)
    Esq., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $678.76k
  • Mr. A. Ernest Toth Jr. (Age 64)
    Chief Financial Officer
  • Ms. Cassie Jung (Age 44)
    Sr. VP of Operations
  • Mr. Peter E. Boyd (Age 57)
    Sr. VP of IT, HR & Communications
  • Mr. Kenneth W. Marshall (Age 64)
    Chief Commercial Officer
  • Dr. Gary H. Slatko M.D. (Age 66)
    MBA, Chief Medical Officer
  • Dr. Stephen Wargacki (Age 45)
    Sr. VP of R&D
  • Dr. Carl N. Kraus M.D. (Age 53)
    Chief Medical Officer













AQST Stock - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price forecast for 2023?

4 Wall Street research analysts have issued 12 month price targets for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2023?

Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of the year. Since then, AQST stock has increased by 66.3% and is now trading at $1.50.
View the best growth stocks for 2023 here
.

Are investors shorting Aquestive Therapeutics?

Aquestive Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,820,000 shares, a drop of 7.1% from the August 15th total of 1,960,000 shares. Based on an average daily trading volume, of 374,400 shares, the days-to-cover ratio is presently 4.9 days.
View Aquestive Therapeutics' Short Interest
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our AQST earnings forecast
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm earned $13.24 million during the quarter, compared to analyst estimates of $10.76 million.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $44.00 million-$48.00 million, compared to the consensus revenue estimate of $43.37 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.99%), Geode Capital Management LLC (0.67%), BlackRock Inc. (0.66%), Walleye Capital LLC (0.65%), Marshall Wace LLP (0.44%) and Acadian Asset Management LLC (0.29%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd.
View institutional ownership trends
.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $1.50.

How much money does Aquestive Therapeutics make?

Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $100.10 million and generates $47.68 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Aquestive Therapeutics have?

The company employs 130 workers across the globe.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.

This page (NASDAQ:AQST) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -